DNDi in "patent-free" antimalarial drug deal
The Drugs for Neglected Diseases initiative (DNDi) has announced its second non-patented pharmaceutical R&D project for a malaria therapy, following the launch of an earlier product in association with France-based drug major Sanofi-Aventis (Marketletter March 26, 2007). The DNDi was founded in 2002 as a joint venture of Medecins Sans Frontieres and a number of organizations worldwide, including the Institut Pasteur, the Oswaldo Cruz Foundation, the Kenya Medical Research Institute, Malaysia's Ministry of Health and the Indian Council of Medical Research.
The new project is a partnership, under the DNDi's Fixed-dose Artesunate-based Combination Therapies (FACT) program, with Brazil's leading public drugmaker, Farmanguinhos/Fiocruz, to develop ASMQ (artesunate/mefloquine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze